| Autor: |
Polesso, Fanny, Munks, Michael W., Rott, Katherine H., Smart, Savannah, Hill, Ann B., Moran, Amy E. |
| Předmět: |
|
| Zdroj: |
European Journal of Immunology; Jun2021, Vol. 51 Issue 6, p1473-1481, 9p |
| Abstrakt: |
Therapeutic antibodies blocking PD‐1‐/PD‐L1 interaction have achieved remarkable clinical success in cancer. In addition to blocking a target molecule, some isotypes of antibodies can activate complement, NK cells or phagocytes, resulting in death of the cell expressing the antibody's target. Human anti‐PD‐1 therapeutics use antibody isotypes designed to minimize such antibody‐dependent lysis. In contrast, anti‐PD‐1 reagents used in mice are derived from multiple species, with different isotypes, and are not engineered to reduce target cell death: few studies analyze or discuss how antibody species and isotype may impact data interpretation. We demonstrate here that anti‐PD‐1 therapy to promote activation and proliferation of murine PD‐1‐expressing CD8 T cells sometimes led instead to a loss of antigen specific cells. This phenomenon was seen in two tumor models and a model of virus infection, and varied with the clone of anti‐PD‐1 antibody. Additionally, we compared competition among anti‐PD‐1 clones to find a combination that allows detection of PD‐1‐expressing cells despite the presence of blocking anti‐PD1 antibodies in vivo. These data bring attention to the possibility of unintended target cell depletion with some commonly used anti‐mouse PD‐1 clones, and should provide a valuable resource for the design and interpretation of anti‐PD‐1 studies in mice. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text